Medical Pharmacology: Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension

Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension
Tier: Tier 2 — Conceptual Understanding

1. A 73-year-old man with ISH (BP 172/68 mmHg) and no other comorbidities is started on chlorthalidone 12.5 mg daily. At 6 weeks his BP is 154/62 mmHg — improved but still above target — and his serum sodium is 136 mEq/L, potassium 3.6 mEq/L. His physician wants to add amlodipine 5 mg. Before doing so, she notes his diastolic has fallen to 62 mmHg. How should the low diastolic guide the clinical decision?

A) The low diastolic is irrelevant — diastolic BP has no clinical significance in ISH management; only systolic BP determines cardiovascular risk and treatment targets in elderly patients; amlodipine should be added without reservation.
B) The falling diastolic is an important clinical signal in the context of ISH management — his baseline DBP of 68 mmHg has already fallen to 62 mmHg on chlorthalidone alone; adding amlodipine (an arteriolar vasodilator) may reduce DBP further toward or below the 65 mmHg J-curve threshold, potentially impairing coronary diastolic perfusion; the most appropriate approach is to add amlodipine at the lowest dose (2.5 mg) with close monitoring of standing DBP and symptoms of coronary underperfusion (angina, dizziness, exertional dyspnea), accepting a potentially more modest SBP reduction target.
C) The low diastolic confirms that his ISH is fully treated and no additional antihypertensive is needed — a DBP below 65 mmHg indicates the aortic compliance has been restored by chlorthalidone; the SBP of 154 mmHg will self-correct once the diastolic is maintained below 65 mmHg.
D) The low diastolic indicates underhydration from chlorthalidone — isotonic saline 1 L IV should be administered to restore intravascular volume before adding any further antihypertensive; BP management cannot proceed until the diastolic is above 70 mmHg.
E) The low diastolic is a contraindication to all further antihypertensive therapy — any DBP below 70 mmHg in an elderly ISH patient mandates complete withdrawal of all antihypertensives and transition to lifestyle management only.

ANSWER: B

Rationale:

The diastolic BP trajectory in this patient is clinically important and must guide the decision to add a second antihypertensive. His baseline DBP of 68 mmHg has already declined to 62 mmHg on chlorthalidone — placing him at or near the J-curve threshold of 65 mmHg below which coronary diastolic perfusion may be compromised, particularly in elderly patients with likely underlying subclinical coronary artery disease and reduced coronary reserve. Adding amlodipine 5 mg — which produces arteriolar vasodilation and can reduce DBP by 4–8 mmHg — risks pushing the standing DBP (which is already lower than sitting) below a critically low level. The appropriate approach is: add amlodipine at the lowest dose (2.5 mg) rather than 5 mg, focusing on achieving additional SBP reduction while minimizing further DBP decline; monitor both sitting and standing DBP at every visit; counsel the patient to report any new anginal symptoms, exertional dyspnea, or dizziness; and accept that the SBP target may need to be relaxed to 140–150 mmHg (ESH-aligned) rather than below 130 mmHg to protect the DBP.

Option A: Option A is incorrect because DBP has substantial clinical significance in elderly ISH — the J-curve phenomenon and risk of coronary hypoperfusion when DBP falls below 65 mmHg are well-established; dismissing DBP entirely in ISH management is clinically inappropriate.
Option C: Option C is incorrect because a falling DBP in ISH does not indicate aortic compliance restoration — it reflects the consequence of arteriolar dilation and volume depletion from treatment, not physiological reversal of arterial stiffness; ISH cannot be "fully treated" pharmacologically.
Option D: Option D is incorrect because the low diastolic does not indicate clinical dehydration requiring IV saline — it reflects the hemodynamic effect of thiazide-induced volume reduction and arteriolar dilation; IV saline to raise DBP before adding antihypertensives is not the standard clinical approach.
Option E: Option E is incorrect because a DBP below 70 mmHg is not an absolute contraindication to all further antihypertensive therapy — it is a signal for caution and careful selection and dosing of the next agent; the J-curve threshold is 65 mmHg, not 70 mmHg.

2. A 78-year-old man with ISH, heart failure with preserved ejection fraction (HFpEF, EF 58%), and eGFR 52 mL/min/1.73m² is on amlodipine 5 mg daily and lisinopril 5 mg daily. His BP is 158/70 mmHg. His physician considers adding chlorthalidone for additional BP lowering and volume management in HFpEF. Which of the following best describes the pharmacological rationale and the specific caution relevant to this patient?

A) Chlorthalidone is contraindicated in HFpEF — thiazide diuretics worsen diastolic dysfunction by causing volume depletion that reduces LV filling pressure below the threshold required to maintain cardiac output; a loop diuretic should always be used instead in HFpEF patients.
B) Chlorthalidone is appropriate in HFpEF for both BP control and volume management; the specific caution in this patient is hyponatremia risk — at eGFR 52 mL/min/1.73m², the thiazide diuretic effect remains active but renal sodium conservation may be impaired; the risk of hyponatremia is amplified by the concurrent ACEi (lisinopril), which promotes sodium excretion; starting at 6.25 mg with sodium monitoring within 2 weeks is appropriate.
C) Chlorthalidone is not effective at eGFR below 60 mL/min/1.73m² — thiazide diuretics require intact proximal tubular secretion that is abolished at this eGFR; a loop diuretic such as furosemide should be substituted at eGFR below 60 for all diuretic indications.
D) Chlorthalidone provides pharmacological benefit for both BP and volume management in this HFpEF patient; the specific pharmacological caution is the concurrent ACEi: lisinopril reduces aldosterone-mediated potassium excretion while chlorthalidone promotes potassium wasting through NCC inhibition and secondary aldosterone activation — the net electrolyte effect depends on the balance of these opposing mechanisms; monitoring potassium at 2–4 weeks is essential, with particular attention given that his eGFR of 52 mL/min/1.73m² reduces potassium renal excretion capacity, creating a risk for either hyperkalemia (ACEi-dominant) or hypokalemia (chlorthalidone-dominant) depending on the relative pharmacological balance.
E) Chlorthalidone should be replaced with spironolactone — spironolactone's mineralocorticoid receptor blockade specifically improves myocardial fibrosis in HFpEF and is the preferred diuretic agent in all HFpEF patients; thiazide diuretics have no role in HFpEF management.

ANSWER: D

Rationale:

Chlorthalidone is an appropriate addition in this patient with HFpEF, ISH, and an eGFR of 52 mL/min/1.73m² — thiazide-like diuretics retain meaningful diuretic and antihypertensive activity down to eGFR approximately 30–40 mL/min/1.73m², and the patient's eGFR of 52 is above this threshold. The specific pharmacological complexity in this patient is the competing electrolyte effects of the combined chlorthalidone and lisinopril. Chlorthalidone inhibits NCC in the distal convoluted tubule, causing natriuresis and secondary hyperaldosteronism (through volume contraction), which drives potassium wasting in the collecting duct — risk of hypokalemia. Lisinopril reduces angiotensin II-mediated aldosterone secretion, reducing collecting duct potassium secretion — risk of hyperkalemia. In a patient with eGFR 52 mL/min/1.73m², reduced renal potassium excretion capacity further modifies this balance. The net effect is unpredictable — potassium may rise, fall, or remain stable depending on the relative dominance of each mechanism. Monitoring potassium (and sodium and creatinine) at 2–4 weeks after starting chlorthalidone is essential. Option B is partially correct (hyponatremia risk is real) but incomplete — the more pharmacologically nuanced and specific concern in a patient on both lisinopril and chlorthalidone with CKD stage 3a is the competing potassium effects; option D is more complete.

Option A: Option A is incorrect because chlorthalidone is not contraindicated in HFpEF — thiazide diuretics are used in HFpEF for volume management; and while excessive volume depletion reducing LV filling is a concern, this is managed by monitoring symptoms and potassium/creatinine rather than avoiding the drug class entirely.
Option C: Option C is incorrect because thiazide diuretics are not ineffective below eGFR 60 — they retain meaningful diuretic activity down to approximately eGFR 30–40; the clinical threshold for switching to loop diuretics is typically eGFR below 30–40, not 60.
Option E: Option E is incorrect because spironolactone is not the universally preferred diuretic in all HFpEF patients — while it has been studied in HFpEF (TOPCAT trial — modest benefit in some analyses), it carries hyperkalemia risk particularly in CKD; and thiazide diuretics have an established role in HFpEF management.

3. A 70-year-old man has ISH (BP 168/74 mmHg) and gout (three episodes in the past two years, currently on allopurinol 300 mg daily). He is not on any antihypertensive. His physician is choosing between chlorthalidone and amlodipine as first-line therapy. Which of the following best addresses this choice?

A) Amlodipine is the preferred first-line choice in this patient — chlorthalidone raises serum uric acid through reduced renal uric acid excretion (competing with urate for organic anion transporter secretion in the proximal tubule) and can precipitate acute gout attacks even in patients on allopurinol; amlodipine lowers BP through L-type calcium channel blockade without affecting uric acid metabolism, making it pharmacologically appropriate for a patient with active gout; if additional BP control is needed, a RAAS inhibitor (losartan has a uricosuric effect) can be added rather than a thiazide.
B) Chlorthalidone is preferred because allopurinol prevents all thiazide-induced uric acid elevation — xanthine oxidase inhibition by allopurinol completely eliminates the uricosuria-reducing effect of chlorthalidone, making gout a non-issue for patients already on allopurinol.
C) Neither chlorthalidone nor amlodipine is appropriate in gout — both drug classes elevate uric acid through xanthine oxidase activation; only RAAS inhibitors are safe antihypertensives in patients with gout.
D) Chlorthalidone is preferred regardless of gout status — the SHEP trial evidence is so compelling for elderly ISH that gout history should never influence the first-line agent choice; gout can be managed by increasing allopurinol to 600 mg daily if needed.
E) Both chlorthalidone and amlodipine have identical effects on uric acid — the choice between them is purely based on cardiovascular trial evidence; gout is not a pharmacological consideration when selecting between these two agents.

ANSWER: A

Rationale:

Gout history is a pharmacologically relevant factor when choosing between chlorthalidone and amlodipine for first-line ISH treatment. Thiazide and thiazide-like diuretics (including chlorthalidone) raise serum uric acid through a well-characterized mechanism: they compete with uric acid for secretion by organic anion transporters (OAT1/OAT3) in the proximal tubule — by occupying these transporters, thiazides reduce uric acid tubular secretion, increasing plasma uric acid. This hyperuricemia can precipitate acute gout in susceptible patients even when they are on allopurinol (which reduces uric acid production through xanthine oxidase inhibition but does not fully eliminate the effect of reduced tubular secretion). Amlodipine, in contrast, lowers BP through arteriolar L-type calcium channel blockade with no effect on uric acid metabolism — it is pharmacologically neutral for gout risk. For a patient with active gout (three episodes in two years) who is already on allopurinol, amlodipine is the more appropriate first-line antihypertensive. An additional pharmacological consideration: if a second agent is needed, losartan (an ARB) has a mild uricosuric effect — it inhibits urate reabsorption in the proximal tubule, slightly lowering uric acid — making it a pharmacologically favorable add-on in hypertensive patients with gout.

Option B: Option B is incorrect because allopurinol does not completely eliminate the thiazide-induced uric acid elevation — allopurinol reduces uric acid production (xanthine oxidase inhibition) while thiazides impair uric acid excretion (tubular secretion inhibition); these are independent mechanisms, and thiazides can still raise uric acid and precipitate gout despite allopurinol therapy.
Option C: Option C is incorrect because amlodipine does not elevate uric acid — DHP CCBs have no effect on xanthine oxidase or uric acid metabolism; only thiazide diuretics are associated with uric acid elevation.
Option D: Option D is incorrect because gout history is a legitimate pharmacological consideration in antihypertensive selection — choosing chlorthalidone over amlodipine in a patient with active gout without considering the uricosuria effect is clinically inappropriate.
Option E: Option E is incorrect because chlorthalidone and amlodipine have distinctly different effects on uric acid — chlorthalidone raises uric acid through tubular secretion inhibition while amlodipine has no uric acid effect; gout is a pharmacologically important differentiator between these agents.

4. A geriatrician is reviewing an 86-year-old woman with BP 174/62 mmHg who has been on no antihypertensive therapy. She has CFS 4 (vulnerable), lives alone with twice-weekly carer support, and her 10-year ASCVD risk calculation is not applicable at this age. The family asks why treatment was not started years ago and whether starting now is "too late." Which of the following best addresses the evidence base for starting antihypertensives in a patient of this age?

A) Starting antihypertensives above age 85 is not evidence-based — all landmark trials in elderly hypertension enrolled patients below age 82; no data supports treatment initiation above this age and therapy should be deferred.
B) Treatment is too late to be beneficial above age 85 — the cardiovascular benefit of antihypertensive therapy requires at least 15 years of treatment before event reduction is detectable; patients starting at 86 will not survive long enough to derive any benefit.
C) HYVET enrolled patients aged 80 or older with a mean age of 83.6 years and demonstrated significant all-cause mortality reduction (21%) and heart failure reduction (64%) with indapamide ± perindopril; importantly, the trial showed benefit emerging within the trial period (median follow-up 1.8 years) — not after decades; this patient at 86 with CFS 4 (vulnerable but not yet frail) is within the population where HYVET demonstrated benefit; starting indapamide 1.25 mg or amlodipine 2.5 mg at the lowest dose with the start-low, go-slow principle and close monitoring is evidence-based and appropriate.
D) Treatment should be started only if the patient has had a prior cardiovascular event — HYVET enrolled only secondary prevention patients with prior stroke or MI; primary prevention above age 80 is not supported by evidence.
E) Starting antihypertensives at age 86 will cause immediate cognitive impairment from hypoperfusion — the elderly brain requires higher BP for adequate perfusion, and any pharmacological BP reduction in patients above age 80 causes irreversible cerebral ischemia.

ANSWER: C

Rationale:

HYVET specifically addressed the question of whether treatment is beneficial in very elderly patients. The trial enrolled 3,845 patients aged 80 or older with a mean age of 83.6 years — directly encompassing the population of this 86-year-old patient. Critically, the cardiovascular benefit emerged within the trial's median follow-up of 1.8 years: a 21% reduction in all-cause mortality (statistically significant) and 64% reduction in heart failure were demonstrated within less than 2 years of treatment initiation. This directly refutes the argument that elderly patients cannot live long enough to benefit — the benefit accrues relatively quickly. For this patient with CFS 4 (vulnerable but not dependent), treatment is appropriate with the start-low, go-slow approach: initiate at the lowest dose (indapamide 1.25 mg or amlodipine 2.5 mg), set a target of 140–149 mmHg SBP consistent with ESH 2023 guidance for patients aged 80 or older, assess sitting and standing BP, monitor electrolytes within 2–4 weeks, and review the regimen regularly as frailty evolves.

Option A: Option A is incorrect because HYVET enrolled patients aged 80 or older with a mean age of 83.6 years — the evidence base extends to patients in their mid-to-late 80s; the claim that no evidence exists above age 82 is factually incorrect.
Option B: Option B is incorrect because HYVET demonstrated mortality and cardiovascular benefit within a median follow-up of 1.8 years — not 15 years; the benefit accrual time for antihypertensive therapy is measured in months to low single-digit years, not decades.
Option D: Option D is incorrect because HYVET enrolled patients without requiring a prior cardiovascular event — it was a primary and secondary prevention trial and its evidence supports treatment in elderly patients without mandatory prior cardiovascular events.
Option E: Option E is incorrect because HYVET demonstrated that antihypertensive treatment in patients aged 80 or older does not cause harm — indeed, serious adverse events were fewer in the active treatment arm than placebo; and cognitive impairment from antihypertensive-induced hypoperfusion is not an inevitable consequence of pharmacological BP reduction at moderate targets.

5. A 74-year-old woman with ISH, osteoporosis, and a prior wrist fracture asks whether any of her antihypertensive medications affect bone density or fracture risk. She is on chlorthalidone 12.5 mg and amlodipine 5 mg. Which of the following correctly addresses this question?

A) Amlodipine reduces bone density by blocking calcium channels in osteoblasts — calcium channel blockade prevents calcium uptake by bone-forming cells, reducing trabecular bone mineral density; amlodipine should be switched to a diuretic in all osteoporotic elderly patients.
B) Chlorthalidone increases fracture risk through hypokalemia-induced muscle weakness — potassium depletion from thiazide diuretics impairs neuromuscular function, reducing gait stability and increasing the risk of falls and hip fracture; potassium supplementation eliminates this risk completely.
C) Both chlorthalidone and amlodipine have no effect on bone density or fracture risk — antihypertensive medications are pharmacologically inert with respect to calcium metabolism and bone health; the patient's osteoporosis management is independent of her antihypertensive regimen.
D) Thiazide and thiazide-like diuretics (including chlorthalidone) have a favorable effect on bone density — they reduce renal calcium excretion by increasing calcium reabsorption in the distal convoluted tubule, raising serum calcium availability for bone mineralization; epidemiological data associate thiazide diuretic use with reduced hip fracture risk; this is an additional benefit of chlorthalidone beyond BP lowering in this osteoporotic patient; amlodipine has no specific effect on bone metabolism.
E) Thiazide and thiazide-like diuretics reduce urinary calcium excretion through their DCT action, producing a calcium-sparing effect that is associated epidemiologically with modestly reduced fracture risk — this is a beneficial secondary property of chlorthalidone in this osteoporotic patient; amlodipine is calcium-channel-blocking in vascular smooth muscle but has high vascular selectivity and no meaningful effect on calcium absorption or bone mineralization at clinical doses; neither agent increases fracture risk.

ANSWER: E

Rationale:

The question of antihypertensive effects on bone health is clinically relevant in elderly osteoporotic patients. Thiazide and thiazide-like diuretics — including chlorthalidone — have a specific and pharmacologically favorable effect on calcium metabolism. In the distal convoluted tubule, thiazides inhibit the NCC cotransporter, reducing intracellular sodium. This lowered intracellular sodium concentration enhances the activity of the basolateral Na-Ca exchanger, increasing calcium reabsorption from the tubular lumen into the peritubular capillaries — a calcium-sparing effect. Urinary calcium excretion falls, and serum calcium availability is modestly increased. Epidemiological studies and meta-analyses have consistently associated thiazide diuretic use with reduced hip fracture risk in the elderly — an additional benefit beyond BP lowering that makes thiazides particularly well-suited for elderly osteoporotic patients. Amlodipine blocks L-type calcium channels in vascular smooth muscle at the doses used for hypertension — it has high vascular selectivity and negligible effect on calcium absorption from the gut or on osteoblast/osteoclast calcium handling at clinical doses; it does not affect bone mineralization. Option D is pharmacologically accurate and closely matches option E — both correctly describe the calcium-sparing mechanism and reduced fracture risk association with thiazides and the neutral effect of amlodipine; option E is more complete in also explicitly stating that neither agent increases fracture risk, which is the key reassurance the patient needs.

Option A: Option A is incorrect because amlodipine does not reduce bone density through osteoblast calcium channel blockade — DHP CCBs have high vascular selectivity at clinical doses; osteoblast effects would require tissue concentrations not achieved at antihypertensive doses.
Option B: Option B is incorrect because while hypokalemia from thiazides can contribute to muscle weakness and falls risk, this is managed by potassium monitoring and supplementation — it is not the primary bone-density question; and potassium supplementation alone does not fully eliminate all fall-related fracture risk.
Option C: Option C is incorrect because thiazide diuretics do have a specific and favorable effect on bone metabolism through calcium reabsorption enhancement — describing antihypertensives as universally inert with respect to calcium metabolism is pharmacologically incorrect.

6. A 69-year-old woman with ISH (BP 164/72 mmHg) and no comorbidities is considering whether to start antihypertensive therapy. She is concerned about "becoming dependent on pills" and asks what happens to BP if she starts therapy and then stops. Which of the following best addresses the pharmacological reality of antihypertensive treatment in elderly ISH?

A) Antihypertensive therapy creates permanent physiological dependence — the cardiovascular system adapts to lower BP, and stopping medication causes a hypertensive crisis more severe than the pre-treatment BP in 90% of patients; this dependence should be disclosed before treatment.
B) When antihypertensives are stopped in patients with ISH, BP generally returns toward the pre-treatment level over days to weeks — there is no evidence that antihypertensive therapy worsens the underlying disease or causes higher BP than would have occurred without treatment; the cardiovascular benefits accrued during treatment (e.g., reduced LVH, reduced atherosclerotic progression) may persist partially even after stopping; if she later decides to stop, gradual tapering is preferred over abrupt discontinuation for some agents (beta-blockers, clonidine) to avoid rebound, but chlorthalidone and amlodipine can be stopped without rebound hypertension; her concern about "dependence" reflects a common misunderstanding of the pharmacology.
C) Starting antihypertensives permanently alters the renin-angiotensin-aldosterone system in a way that makes future hypertension unresponsive to therapy — patients who stop antihypertensives after more than 2 years of treatment must switch drug classes because RAAS adaptation renders the original agents ineffective.
D) Antihypertensive therapy is irreversible in elderly patients — once started, it should never be stopped because abrupt withdrawal causes permanent elevation of BP above pre-treatment levels through baroreceptor resetting at a higher threshold; the risk of stopping outweighs any potential benefit of discontinuation.
E) In elderly patients with ISH driven by arterial stiffness, antihypertensives gradually reverse the arterial stiffness that drives ISH — after 3–5 years of treatment, the underlying arterial biology is restored and medications can be permanently stopped without BP returning to pre-treatment levels.

ANSWER: B

Rationale:

This patient's concern about becoming "dependent" on antihypertensive medication reflects a common misconception that warrants clear pharmacological explanation. When antihypertensive therapy is stopped in elderly ISH patients, BP returns toward the pre-treatment level over a variable period (days to weeks) — the drug's effect wanes as it is eliminated from the body. There is no evidence that antihypertensive treatment causes the underlying arterial stiffness to worsen or that stopping treatment results in BP higher than the original pre-treatment level. Important pharmacological nuances: agents like chlorthalidone (diuretic) and amlodipine (DHP CCB) can be stopped without a significant rebound hypertension effect — their BP-lowering mechanisms are directly tied to drug presence; once the drug is cleared, BP returns toward baseline. This contrasts with beta-blockers and clonidine, where the suppression of sympathetic tone leads to rebound tachycardia (beta-blockers) or hypertensive crisis (clonidine) on abrupt withdrawal — these require gradual tapering. Some cardiovascular benefits from BP control (regression of LVH, slowing of atherosclerosis) may persist partially after stopping, but BP itself will rise. The "dependence" framing is pharmacologically inaccurate — the ongoing need for medication reflects the persistence of the underlying disease (arterial stiffness), not pharmacological addiction.

Option A: Option A is incorrect because antihypertensive therapy does not create physiological dependence in the addiction sense — BP returns toward baseline when treatment stops; post-withdrawal BP exceeding pre-treatment BP does not occur with most antihypertensives including chlorthalidone and amlodipine.
Option C: Option C is incorrect because antihypertensives do not cause RAAS adaptation rendering future therapy ineffective — the underlying disease mechanisms remain responsive; switching drug classes after stopping is not required.
Option D: Option D is incorrect because stopping antihypertensives (particularly first-line agents like chlorthalidone and amlodipine) does not cause permanent BP elevation above pre-treatment levels through baroreceptor resetting — BP returns to near pre-treatment levels.
Option E: Option E is incorrect because antihypertensive therapy does not reverse the arterial stiffness that drives ISH — reducing BP with medication does not restore elastin, reduce collagen cross-linking from AGEs, or reverse medial calcification; BP will rise toward pre-treatment levels if medication is stopped.

7. An 80-year-old man with ISH is on indapamide 1.25 mg and perindopril 4 mg (the HYVET regimen). At review, his BP is 136/68 mmHg — at the ESH target. His eGFR has declined from 64 to 54 mL/min/1.73m² over 12 months. Potassium is 5.3 mEq/L. Which of the following best addresses the management of the declining renal function and rising potassium in this context?

A) Stop perindopril immediately — any rise in creatinine or potassium on an ACEi mandates immediate discontinuation; the 10-point eGFR decline is a sign of renovascular disease requiring urgent renal artery imaging.
B) Stop both indapamide and perindopril immediately — the dual RAAS-diuretic combination is causing progressive AKI; neither agent should be used in patients with eGFR below 60 mL/min/1.73m².
C) Increase the perindopril dose to 8 mg — higher RAAS inhibition will provide more renoprotection and prevent further eGFR decline; the potassium rise is transient and does not require intervention.
D) The eGFR decline from 64 to 54 mL/min/1.73m² over 12 months warrants review — an eGFR fall of 10 mL/min over 12 months (15.6%) is above the threshold that would prompt reassessment; however, distinguishing a hemodynamic eGFR decline from ACEi-mediated efferent arteriolar dilation (which is expected and acceptable up to 20–30% from baseline without necessarily indicating structural injury) from true progressive CKD or renovascular disease is clinically important; potassium of 5.3 mEq/L is approaching the threshold of concern; if the decline is hemodynamic (stable proteinuria, no structural imaging concern), continue with monitoring; if the decline is progressive structural injury or potassium reaches 5.5 mEq/L, reduce the perindopril dose or consider substituting another agent; sick-day guidance (hold perindopril during intercurrent illness/dehydration) should be reinforced.
E) The declining eGFR indicates the indapamide is causing progressive AKI — thiazide-like diuretics are nephrotoxic at eGFR below 60 mL/min/1.73m²; replace indapamide with furosemide immediately.

ANSWER: D

Rationale:

The eGFR decline in this patient on perindopril requires careful clinical interpretation. ACEi and ARBs reduce glomerular filtration pressure by dilating the efferent arteriole — a hemodynamic effect that can produce a pharmacologically expected eGFR decline of up to 20–30% from baseline. This hemodynamic decline does not represent structural kidney injury and does not necessarily mandate drug discontinuation — it reflects the mechanism of intraglomerular pressure reduction that also provides renoprotective benefit in proteinuric kidney disease. However, this patient's eGFR has fallen 15.6% (from 64 to 54) over 12 months — at the upper boundary of the acceptable hemodynamic range. His potassium of 5.3 mEq/L is approaching but not yet at the 5.5 mEq/L threshold that typically triggers ACEi dose reduction or discontinuation. Clinically appropriate steps: review proteinuria trajectory (structural injury is suggested by rising proteinuria); consider renal imaging if clinical features suggest renovascular disease; if the eGFR decline appears hemodynamic and non-progressive, continue with increased monitoring frequency; reinforce sick-day guidance (hold perindopril during dehydration, vomiting, diarrhea, or heat exposure); if potassium reaches 5.5 mEq/L or eGFR continues to decline, reduce perindopril dose.

Option A: Option A is incorrect because the eGFR decline may be hemodynamic rather than structural — immediate discontinuation at any creatinine rise is overly aggressive; and the eGFR decline alone does not diagnose renovascular disease requiring urgent imaging without supporting clinical features.
Option B: Option B is incorrect because neither indapamide nor perindopril is contraindicated at eGFR 54 — thiazide-like diuretics retain efficacy down to approximately eGFR 30–40, and ACEi are used in CKD with careful monitoring; stopping both agents would sacrifice the cardiovascular and BP benefits established in HYVET.
Option C: Option C is incorrect because increasing perindopril in a patient with a potassium of 5.3 mEq/L and declining eGFR would worsen both the hyperkalemia and the eGFR — dose escalation is the opposite of the appropriate response.
Option E: Option E is incorrect because indapamide is not nephrotoxic and the declining eGFR is more plausibly attributed to the ACEi (efferent arteriolar dilation reducing GFR) than to the thiazide; furosemide substitution is not indicated at eGFR 54.

8. A 75-year-old man with ISH and type 2 diabetes (HbA1c 7.4%, on metformin and sitagliptin) is started on chlorthalidone 12.5 mg daily. At 8 weeks, his fasting glucose has risen from 112 mg/dL to 134 mg/dL and his HbA1c from 7.4% to 7.8%. His BP is now 136/70 mmHg. Which of the following best explains this glycemic change and the appropriate management?

A) Chlorthalidone causes hyperglycemia through multiple mechanisms: hypokalemia from potassium wasting reduces pancreatic beta-cell insulin secretion (potassium is required for membrane depolarization triggering insulin release); volume contraction and compensatory sympathetic activation increase hepatic glucose output and reduce peripheral glucose uptake; the glycemic effect is dose-dependent and more pronounced with chlorthalidone than HCTZ due to its longer half-life and more sustained diuretic effect; management: check and correct potassium (his potassium should be measured — if below 3.5 mEq/L, supplementation is required); assess whether the glycemic change is clinically significant for his diabetes management; if hypokalemia-driven, correcting potassium may partially reverse the glucose rise; consider switching to amlodipine if glycemic worsening cannot be managed.
B) Chlorthalidone has no effect on glucose metabolism — the glycemic rise is caused by sitagliptin inducing glucagon secretion that outweighs its GLP-1-mediated benefit; sitagliptin should be discontinued.
C) The glucose rise is caused by a drug interaction between chlorthalidone and metformin — metformin inhibits the renal tubular secretion of chlorthalidone, causing chlorthalidone accumulation and hyperglycemia through sodium retention triggering insulin resistance.
D) The glycemic worsening is a sign of type 1 diabetes developing independently of the antihypertensive — autoimmune beta-cell destruction requires urgent insulin initiation; chlorthalidone is not causally related.
E) Chlorthalidone at 12.5 mg has no clinically meaningful effect on glucose metabolism — the glycemic rise is entirely due to dietary non-adherence during the monitoring period; no antihypertensive medication adjustment is needed.

ANSWER: A

Rationale:

Thiazide and thiazide-like diuretics cause hyperglycemia through two complementary mechanisms. The primary mechanism is hypokalemia-mediated impairment of insulin secretion: potassium is required for the membrane depolarization of pancreatic beta cells that triggers insulin vesicle exocytosis; when serum potassium falls below approximately 3.5 mEq/L, beta-cell insulin secretion is impaired, raising fasting glucose. Chlorthalidone causes more pronounced hypokalemia than HCTZ due to its longer half-life (40–60 hours) and more sustained natriuresis, producing greater secondary aldosterone-mediated potassium wasting. The secondary mechanism is the compensatory sympathetic activation from volume contraction, which increases hepatic gluconeogenesis and reduces peripheral insulin sensitivity. The management approach is pharmacologically rational: measure potassium — if below 3.5 mEq/L, correcting the hypokalemia with supplementation may partially or fully reverse the glucose elevation; if potassium is normal (above 3.5 mEq/L), the hyperglycemia is driven by other mechanisms and the glycemic impact must be weighed against the BP benefit; if the diabetes becomes poorly controlled from the chlorthalidone effect, switching to amlodipine (which has no glycemic effects) is a valid pharmacological alternative.

Option B: Option B is incorrect because sitagliptin is a DPP-4 inhibitor that prevents GLP-1 breakdown — it reduces postprandial glucagon, lowers glucose, and does not cause clinically significant hyperglycemia; the glucose rise is attributable to chlorthalidone, not sitagliptin.
Option C: Option C is incorrect because there is no established pharmacokinetic interaction between metformin and chlorthalidone through OAT competition causing chlorthalidone accumulation and hyperglycemia — the glucose mechanism is pharmacodynamic (potassium-mediated), not pharmacokinetic.
Option D: Option D is incorrect because thiazide-induced hyperglycemia is a well-established pharmacodynamic adverse effect — attributing the glucose rise to new-onset autoimmune type 1 diabetes without any supporting evidence (no autoantibodies, no ketoacidosis) dismisses the obvious temporal association with chlorthalidone initiation.
Option E: Option E is incorrect because chlorthalidone's hyperglycemic effect is clinically real and dose-dependent — the HbA1c rise from 7.4% to 7.8% over 8 weeks is a meaningful glycemic worsening that cannot be attributed entirely to dietary non-adherence without pharmacological consideration.

9. A 77-year-old man with ISH and no other comorbidities is reviewed by his geriatrician. He is on amlodipine 10 mg and indapamide 1.25 mg — his BP is 134/66 mmHg at target. His gait speed is measured at 0.6 m/s (below the 0.8 m/s threshold suggesting pre-frailty to frailty). His Timed Up and Go (TUG) test is 14 seconds (above the 12-second threshold). The geriatrician wants to reassess his BP target in the context of these functional findings. Which of the following is the most appropriate pharmacological response?

A) No change is needed — gait speed and TUG test results are occupational therapy assessments with no pharmacological relevance to antihypertensive management; BP targets are set by age alone.
B) Immediately stop both antihypertensives — any frailty marker mandates complete antihypertensive withdrawal regardless of current BP control or clinical stability.
C) Recognize that slow gait speed and prolonged TUG indicate evolving frailty that modifies the optimal BP target and antihypertensive intensity — his current BP of 134/66 mmHg is within the more aggressive ACC/AHA target but the ESH framework and frailty assessment suggest a target of 140–149 mmHg SBP is more appropriate for his functional status; consider reducing amlodipine from 10 mg to 5 mg as his BP is already at 134 mmHg with some room to accept a modest rise, while reducing the pharmacological burden and potential for adverse effects in a pre-frail/frail patient; reassess frailty every 6–12 months and adjust targets accordingly as functional status evolves.
D) Add a beta-blocker — slow gait speed in elderly patients is caused by reduced cardiac output from undertreated systolic hypertension; adding bisoprolol will improve cardiac output and normalize gait speed.
E) Switch indapamide to furosemide — the slow gait speed indicates fluid retention from inadequate diuresis; furosemide's more potent diuresis will improve mobility by reducing lower extremity edema.

ANSWER: C

Rationale:

Gait speed and the Timed Up and Go test are validated functional assessment tools in geriatric medicine that are directly relevant to antihypertensive management decisions. A gait speed below 0.8 m/s and TUG above 12 seconds are recognized markers of pre-frailty to frailty — they indicate reduced physiological reserve and increased vulnerability to the adverse effects of pharmacological interventions. In the context of the SPRINT elderly subgroup analysis, gait speed specifically emerged as a modifier of treatment benefit: while SPRINT overall showed cardiovascular and mortality benefit from intensive BP lowering in patients aged 75 or older, the benefit appeared attenuated in patients with slower gait speeds — suggesting that the benefit-risk trade-off is less favorable in functionally impaired elderly patients. For this patient, his current BP of 134/66 mmHg reflects tight BP control that is appropriate for a fit elderly patient (ACC/AHA framework) but may be more aggressive than needed given his functional markers of pre-frailty. The ESH 2023 target of 140–149 mmHg for patients aged 80 or older, and its emphasis on frailty individualization, supports considering a modest relaxation of his target — reducing amlodipine from 10 mg to 5 mg may allow SBP to rise toward 140–145 mmHg while reducing the pharmacological burden and associated adverse-effect risk (orthostatic hypotension, falls).

Option A: Option A is incorrect because gait speed and TUG are validated, evidence-supported tools that have been specifically examined in antihypertensive clinical trials (SPRINT subgroup analysis) — they are directly pharmacologically relevant to BP target individualization.
Option B: Option B is incorrect because frailty markers prompt reassessment and possible de-escalation, not immediate complete withdrawal — the goal is proportionate adjustment, not abrupt cessation.
Option D: Option D is incorrect because slow gait speed in elderly pre-frail patients reflects reduced physical reserve, not cardiac output insufficiency; adding a beta-blocker would worsen exercise tolerance and gait speed through chronotropy and reduced cardiac output.
Option E: Option E is incorrect because slow gait speed is not caused by fluid retention in a patient without ankle edema or HF evidence — furosemide substitution addresses a problem that is not present and introduces risks of volume depletion and orthostatic hypotension.

10. A 72-year-old man with ISH, CKD stage 3b (eGFR 38 mL/min/1.73m²), and no proteinuria is started on antihypertensive therapy. His physician is choosing between chlorthalidone and indapamide. Which of the following best guides the choice and addresses the pharmacological difference between these two agents at this eGFR?

A) Chlorthalidone and indapamide are pharmacologically identical — both are thiazide-like diuretics with the same half-life, mechanism, and clinical activity at all levels of renal function; the choice is arbitrary.
B) Neither chlorthalidone nor indapamide has antihypertensive activity at eGFR below 40 mL/min/1.73m² — both agents are completely ineffective as diuretics in CKD stage 3b; only loop diuretics maintain activity at this GFR.
C) Chlorthalidone is preferred over indapamide at this eGFR — chlorthalidone's longer half-life means it continues to provide antihypertensive effect even as tubular secretion is reduced in CKD; indapamide loses all activity below eGFR 45 mL/min/1.73m².
D) Indapamide should be avoided in CKD — unlike chlorthalidone, indapamide is nephrotoxic at eGFR below 45 mL/min/1.73m² through direct tubular cell toxicity; chlorthalidone has protective effects on tubular cells.
E) Both chlorthalidone and indapamide retain meaningful antihypertensive activity at eGFR 38 mL/min/1.73m² through vasodilatory and natriuretic mechanisms that are partially independent of diuretic potency; indapamide has a more prominent direct vascular smooth muscle relaxation component compared to chlorthalidone, which may maintain antihypertensive efficacy even when diuretic natriuresis is reduced by impaired tubular secretion in CKD; in practice, both agents are used in CKD stage 3b with monitoring; loop diuretics are typically reserved for eGFR below 25–30 mL/min/1.73m² or when significant volume overload is present.

ANSWER: E

Rationale:

Thiazide-like diuretics retain pharmacological activity at eGFR values that were historically thought to limit their use. At eGFR 38 mL/min/1.73m², both chlorthalidone and indapamide maintain meaningful antihypertensive effect — the traditional teaching that thiazides "don't work" below eGFR 30–45 mL/min applies to their diuretic efficacy (natriuresis), but their antihypertensive effect has multiple components. Indapamide is pharmacologically distinct from chlorthalidone in having a more prominent direct vascular smooth muscle relaxation component — reducing systemic vascular resistance independently of natriuresis. This vascular component maintains antihypertensive efficacy even when tubular secretion is reduced by CKD-related nephron loss, potentially making indapamide more reliably effective than chlorthalidone at lower eGFR levels. Clinically, both agents are used in CKD stage 3b (eGFR 30–45 mL/min/1.73m²) in practice — the HYVET trial used indapamide in elderly patients, many of whom had reduced renal function. Loop diuretics are generally reserved for eGFR below 25–30 mL/min/1.73m² (where thiazide-like diuretic activity becomes significantly limited) or for patients requiring volume management beyond what thiazides provide.

Option A: Option A is incorrect because chlorthalidone and indapamide have distinct pharmacological properties — they differ in half-life (chlorthalidone 40–60 hours vs. indapamide approximately 14–18 hours), degree of direct vascular vasodilatory activity (indapamide has more), and to some degree their electrolyte profiles.
Option B: Option B is incorrect because both agents retain antihypertensive activity at eGFR 38 — the statement that they are "completely ineffective" below eGFR 40 overstates the renal threshold for loss of activity; thiazide-like diuretics are used routinely in CKD stage 3b.
Option C: Option C is incorrect because the pharmacological advantage at reduced eGFR is more plausibly with indapamide (vascular component) rather than chlorthalidone (longer half-life); and stating indapamide loses all activity below eGFR 45 is an overstatement.
Option D: Option D is incorrect because indapamide is not nephrotoxic — this is a pharmacologically fabricated adverse effect; both agents are used safely in CKD stage 3b with appropriate monitoring.

11. A 79-year-old woman presents with a BP of 178/66 mmHg. She was recently admitted to hospital for a fall causing a wrist fracture. She is on chlorthalidone 12.5 mg, amlodipine 5 mg, and perindopril 4 mg for ISH. Her sitting-to-standing BP drops from 178/66 to 148/52 mmHg. She lives alone. Her Clinical Frailty Scale is 5 (mildly frail). Which of the following best represents the pharmacological and clinical priorities in this patient?

A) Intensify all three antihypertensive agents — a sitting SBP of 178 mmHg is dangerously elevated and requires immediate dose escalation; the fall and wrist fracture are coincidental and unrelated to the antihypertensive regimen.
B) The immediate priority is addressing the orthostatic hypotension and fall risk — the standing SBP drop of 30 mmHg to 148/52 mmHg with a DBP of 52 mmHg (well below the J-curve threshold) in a recently fallen woman living alone constitutes an acute safety concern that outweighs the cardiovascular benefit of her current sitting SBP target; the appropriate intervention is to reduce antihypertensive burden (e.g., reduce or stop perindopril, reduce amlodipine to 2.5 mg) with close monitoring; her sitting SBP target should be relaxed to 140–150 mmHg per ESH guidance for mildly frail patients; falls risk assessment, physiotherapy referral, and home safety assessment should accompany the pharmacological change.
C) Switch all three agents to clonidine monotherapy — a single centrally acting agent is safer than three peripheral agents in a frail elderly woman with orthostatic hypotension; clonidine provides reliable BP reduction without falls risk.
D) No change is needed — the 30 mmHg SBP drop on standing is within the normal postural variation range for an elderly patient and is not clinically significant; the wrist fracture was caused by osteoporosis, not by a medication-related fall.
E) Add midodrine 5 mg three times daily — midodrine is first-line for drug-induced orthostatic hypotension; adding midodrine allows all three antihypertensives to continue at current doses while eliminating the orthostatic BP drop.

ANSWER: B

Rationale:

This patient presents with a convergence of findings that together define a clinical emergency for fall safety: a 30 mmHg orthostatic SBP drop (exceeding the diagnostic threshold of 20 mmHg), a standing DBP of 52 mmHg (well below the 65 mmHg J-curve threshold and raising coronary perfusion concerns), a recent fall causing a wrist fracture (indicating the orthostatic hypotension is clinically consequential, not just a measurement finding), CFS 5 (mildly frail, with reduced physiological reserve), and she lives alone (no immediate assistance available if she falls again). While her sitting SBP of 178 mmHg is elevated, the standing consequences of her antihypertensive regimen are causing immediate, life-threatening fall risk. The pharmacological priorities: reduce the antihypertensive burden to address the orthostatic problem — reducing or stopping perindopril (which contributes to vasodilation without the specific ISH trial evidence of chlorthalidone and amlodipine) and reducing amlodipine to 2.5 mg are reasonable first steps; relax the sitting SBP target to 140–150 mmHg consistent with ESH guidance for mildly frail patients aged 80 or older (she is approaching 80 at 79); implement non-pharmacological measures.

Option A: Option A is incorrect because intensifying antihypertensives in a patient with a 30 mmHg orthostatic drop and a recent fall is directly dangerous — it would worsen the falls risk.
Option C: Option C is incorrect because clonidine is specifically to be avoided in elderly patients with orthostatic hypotension and falls risk — its central sympatholytic effect impairs the cardiovascular response to position change, worsening OH; and it carries rebound hypertension risk on missed doses.
Option D: Option D is incorrect because a 30 mmHg orthostatic SBP drop definitively meets the criteria for orthostatic hypotension — it is not within normal postural variation; and attributing the fracture to osteoporosis alone without considering medication-related falls risk dismisses the obvious pharmacological contribution.
Option E: Option E is incorrect because midodrine (a peripheral alpha-1 agonist vasopressor) is not first-line for drug-induced orthostatic hypotension in this clinical context — antihypertensive dose reduction is the primary intervention; and midodrine carries the risk of supine hypertension, which in a patient with a sitting BP of 178 mmHg is particularly dangerous.

12. A 74-year-old man with ISH is newly started on amlodipine 5 mg. His physician explains that the drug works by blocking L-type calcium channels in vascular smooth muscle. The patient asks why this lowers BP specifically in ISH driven by arterial stiffness, when the drug is working on resistance arterioles rather than the stiff aorta. Which of the following best answers this pharmacological question?

A) The patient is correct that amlodipine cannot lower BP in ISH — DHP CCBs only work in hypertension caused by increased peripheral vascular resistance, not in ISH caused by arterial stiffness; the physician made an error prescribing it for ISH.
B) Amlodipine lowers BP in ISH by directly chelating the calcium deposits in the aortic media — the calcium-channel blocking property removes calcium from calcified arterial walls, restoring compliance and reducing the pulse pressure that drives ISH.
C) Amlodipine lowers SBP in ISH through two mechanisms despite acting primarily on resistance arterioles: reducing total peripheral resistance through arteriolar vasodilation lowers the mean arterial pressure, which reduces the overall pressure load that the stiff aorta must transmit; additionally, the DHP CCBs produce some direct vasodilatory effect on larger conduit vessels, modestly reducing the amplitude of the pressure wave that the stiff aorta cannot buffer; the net clinical effect is meaningful SBP reduction even though the primary driver of ISH (aortic stiffness) is not directly reversed.
D) Amlodipine lowers BP in ISH through peripheral arteriolar vasodilation reducing total peripheral resistance, which lowers mean arterial pressure; the stiff aorta transmits the systolic pressure wave more completely in ISH precisely because it cannot buffer the wave — but if the wave's overall magnitude is reduced by lowering systemic vascular resistance, the transmitted systolic peak is also lower; amlodipine also has some effect on conduit vessel tone; together these mechanisms produce clinically meaningful SBP reduction in ISH without requiring direct reversal of aortic stiffness; the drug works with the hemodynamics of ISH rather than against them.
E) Amlodipine lowers BP in ISH by blocking calcium channels in the sinoatrial node — heart rate reduction from SA node calcium channel blockade reduces cardiac output, which lowers both systolic and diastolic BP equally; this is identical to the mechanism of verapamil.

ANSWER: D

Rationale:

This is an excellent pharmacological question that reveals a nuanced understanding of ISH hemodynamics. The student's concern — that DHP CCBs act on resistance arterioles, not on the stiff aorta — is pharmacologically accurate but misses the downstream hemodynamic consequence of arteriolar vasodilation in ISH. The mechanism works as follows: DHP CCBs (amlodipine) dilate peripheral resistance arterioles by blocking L-type calcium channels in arteriolar smooth muscle. This reduces systemic vascular resistance (SVR) and lowers mean arterial pressure (MAP). In ISH, the elevated SBP reflects both the magnitude of the cardiac output ejected into a stiff aorta and the transmission of that pressure wave. If SVR is reduced, MAP falls, and the absolute systolic pressure generated by the same stroke volume is lower — even though the stiff aorta still cannot buffer the wave, the wave starts from a lower pressure base. Additionally, DHP CCBs have some direct vasodilatory effect on conduit arteries (larger vessels including the aorta), which may modestly reduce pulse wave velocity and aortic stiffness at the margin — though this is not the primary mechanism. The Syst-Eur trial established empirically that DHP CCBs (nitrendipine) produce substantial SBP reduction in ISH (42% stroke reduction) — confirming clinical efficacy despite acting primarily on resistance rather than compliance vessels. Option C is pharmacologically accurate and closely parallels option D but is less complete in explaining the hemodynamic chain; option D more explicitly articulates the mechanism by which arteriolar vasodilation translates to SBP reduction in the specific context of ISH hemodynamics.

Option A: Option A is incorrect because DHP CCBs are specifically established as effective first-line agents for elderly ISH through the Syst-Eur trial — the premise that they cannot work in ISH is directly refuted by major clinical trial evidence.
Option B: Option B is incorrect because amlodipine does not chelate calcium deposits from aortic media — this is pharmacologically impossible; calcium channel blockers block transmembrane calcium ion flux, not structural calcium deposits in vessel walls.
Option E: Option E is incorrect because amlodipine (a DHP CCB) has high vascular selectivity and minimal SA node effects — negative chronotropy is a property of non-DHP CCBs (verapamil, diltiazem); amlodipine does not significantly reduce heart rate.

13. A 76-year-old woman with ISH, prior stroke (18 months ago, no residual deficit), and eGFR 62 mL/min/1.73m² is on no antihypertensive therapy. Her BP is 162/70 mmHg. She is CFS 2 (fit). Which of the following best describes the evidence-based target and first-line pharmacological approach for secondary stroke prevention in this context?

A) In a fit elderly patient with prior stroke and ISH, aggressive BP lowering is particularly important for secondary stroke prevention — current evidence supports a target of below 130/80 mmHg in stroke survivors without significant frailty; first-line agents should include a thiazide-like diuretic (chlorthalidone or indapamide) or a RAAS inhibitor (perindopril), or their combination, both of which have secondary stroke prevention data from the PROGRESS trial (perindopril ± indapamide showing 28% stroke recurrence reduction); her fit status (CFS 2) supports pursuing the more aggressive target with careful monitoring.
B) Prior stroke is a contraindication to antihypertensive therapy in elderly patients — pharmacological BP lowering in stroke survivors risks extending the area of ischemic penumbra and worsening neurological outcomes; BP should not be treated below 160 mmHg after stroke.
C) The only evidence-based antihypertensive for secondary stroke prevention is aspirin — antiplatelet therapy is more effective than antihypertensive therapy for preventing recurrent stroke; antihypertensives have no role in secondary stroke prevention in elderly ISH patients.
D) A beta-blocker should be the first-line agent for secondary stroke prevention after ischemic stroke — beta-blockers reduce cerebral oxygen demand and protect the ischemic penumbra from metabolic injury during BP fluctuations; no other antihypertensive class has equivalent neuroprotective properties.
E) Antihypertensive therapy is not indicated until 6 months post-stroke — the blood-brain barrier is disrupted for 6 months after ischemic stroke, making any pharmacological BP reduction during this period dangerous; treatment should be deferred and then started with a target of below 150 mmHg only.

ANSWER: A

Rationale:

Prior ischemic stroke is one of the most compelling indications for antihypertensive therapy — BP control is the single most effective pharmacological intervention for secondary stroke prevention. Hypertension is the dominant modifiable risk factor for stroke recurrence, and even modest BP reductions produce substantial relative risk reductions for recurrent stroke. The PROGRESS trial (Perindopril Protection Against Recurrent Stroke Study) enrolled 6,105 patients with prior stroke or TIA and demonstrated that perindopril ± indapamide reduced recurrent stroke by 28% (and significantly reduced cognitive decline). This provides specific evidence for the perindopril-indapamide combination — the HYVET regimen — in secondary stroke prevention. For a fit elderly patient (CFS 2), the ACC/AHA 2017 target of below 130/80 mmHg is appropriate; the ESH 2023 framework for this fit patient below 80 years also supports targeting 130–139 mmHg SBP. The combination of a thiazide-like diuretic (indapamide or chlorthalidone) with perindopril (or another RAAS inhibitor) aligns with PROGRESS evidence and standard secondary prevention guidelines. Timing after stroke: treatment is generally initiated or restarted after the acute phase (first 24–72 hours for acute ischemic stroke), not deferred for 6 months.

Option B: Option B is incorrect because antihypertensive therapy is specifically indicated for secondary stroke prevention — the concern about extending ischemic penumbra applies to the acute phase of stroke (first 24–48 hours) when autoregulation is disrupted, not to chronic secondary prevention; 18 months post-stroke, pharmacological BP lowering is evidence-based and important.
Option C: Option C is incorrect because antihypertensives are established as the most effective secondary stroke prevention intervention — aspirin (antiplatelet therapy) addresses a different (thrombotic) component of stroke risk and does not substitute for BP control; both have roles but antihypertensives are not secondary to aspirin for recurrence prevention.
Option D: Option D is incorrect because beta-blockers are not the evidence-based first-line agents for secondary stroke prevention — PROGRESS specifically established perindopril ± indapamide; beta-blockers have no specific "neuroprotective" mechanism in the context of secondary stroke prevention.
Option E: Option E is incorrect because antihypertensive therapy is not routinely deferred for 6 months post-stroke — this patient is 18 months post-stroke, well past the acute phase; and the 6-month deferral period described is not consistent with secondary prevention guidelines.